TITLE:
Eltrombopag Managed Severe Immune Thrombocytopenic Purpura in Pregnancy: A Case Report, Latifa Hospital, DHA, Dubai, UAE
AUTHORS:
Komal Sundeep Hazari, Atif Bashir E. Fazari, Taghrid Gergawi, Hasan Mohamed A. Aal-Yaseen, Nighat Aftab
KEYWORDS:
Immune Thrombocytopenic Purpura, Eltrombopag, Pregnancy
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.9 No.7,
July
18,
2019
ABSTRACT: Immune thrombocytopenic
purpura (ITP) is an acquired autoimmune disorder, defined by a platelet count
of less than 100 × 109/L, secondary
to impaired production and immune destruction of platelets. Bleeding tendency
is the main presentation of this condition. Clinical
symptoms and investigations will confirm the diagnosis. Steroid is the first
line of treatment. Although Rituximab and
Thrombopoietin receptor agonists are useful second line agents in non-pregnant
adults, the data about their role in pregnancy are still limited. We present
the case of a 30 year old primigravida, who was a known case of chronic ITP
since childhood; the course of her disease was fluctuating, for which oral
steroids were used accordingly. She presented with gum bleeding and petechial
rash with very low platelets count. She was sponsored by the Patient Support
Program and was given Eltrombopag during the third trimester. She responded
well to Eltrombopag with no noticeable side effects, neither to the mother nor
to the baby so far. Eltrombopag has been assigned Category C by the Federal
Drugs Agency (FDA) nevertheless there are no well controlled data in the
literature about its role in pregnancy.